PT  - JOURNAL ARTICLE
AU  - Francesco Patalano
AU  - Donald Banerji
AU  - Peter D’Andrea
AU  - Robert Fogel
AU  - Pablo Altman
AU  - Paul Colthorpe
TI  - Addressing unmet needs in the treatment of COPD
AID  - 10.1183/09059180.00004014
DP  - 2014 Sep 01
TA  - European Respiratory Review
PG  - 333--344
VI  - 23
IP  - 133
4099  - http://err.ersjournals.com/content/23/133/333.short
4100  - http://err.ersjournals.com/content/23/133/333.full
SO  - EUROPEAN RESPIRATORY REVIEW2014 Sep 01; 23
AB  - The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting β2-agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium, and the indacaterol/glycopyrronium fixed-dose combination QVA149 have all been shown to significantly improve lung function and patient-reported outcomes. The ability to take medication appropriately is important. Easy to use, low resistance devices may help patients take their medication and achieve good drug deposition. There is a need to optimise COPD management by treating the right patients with the right therapy at the right time during the course of their disease. Herein, we present a view on the current COPD management landscape and current unmet needs, and look to the future of COPD treatment and how patient care can be optimised.